Bonus BioGroup Ltd.

Tel Aviv Stock Exchange BONS.TA

Bonus BioGroup Ltd. EBITDA Margin for the year ending December 31, 2023

Bonus BioGroup Ltd. EBITDA Margin is NA for the year ending December 31, 2023. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
Loading...
Tel Aviv Stock Exchange: BONS.TA

Bonus BioGroup Ltd.

CEO Dr. Shai Meretzki Ph.D.
IPO Date Aug. 12, 2002
Location Israel
Headquarters Matam Advanced Technology Park
Employees 58
Sector Health Care
Industries
Description

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS, as well as other life-threatening acute inflammatory diseases. Its products in pipeline comprise bone augmentation in osteoporosis patients; novel nano-materials for drug delivery; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.

StockViz Staff

January 15, 2025

Any question? Send us an email